[go: up one dir, main page]

Dehelean et al., 2019 - Google Patents

Trends in glycolipid biomarker discovery in neurodegenerative disorders by mass spectrometry

Dehelean et al., 2019

Document ID
5942513324759686475
Author
Dehelean L
Sarbu M
Petrut A
Zamfir A
Publication year
Publication venue
Advancements of Mass Spectrometry in Biomedical Research

External Links

Snippet

Considering the devastating effects of neurodegenerative disorders and the increasing number of people affected by them, an early diagnosis even presymptomatic, prior to serious mental deterioration is necessary. Therefore, screening for biomarkers, especially …
Continue reading at link.springer.com (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry

Similar Documents

Publication Publication Date Title
Leuzy et al. Tau PET imaging in neurodegenerative tauopathies—still a challenge
Hanon et al. Plasma amyloid levels within the Alzheimer's process and correlations with central biomarkers
Ringman et al. Biochemical markers in persons with preclinical familial Alzheimer disease
Formichi et al. Cerebrospinal fluid tau, Ass, and phosphorylated tau protein for the diagnosis of Alzheimer's disease
US8859628B2 (en) Method for preventing, treating and diagnosing disorders of protein aggregation
Thal et al. The role of biomarkers in clinical trials for Alzheimer disease
Huang et al. Biofluid biomarkers of Alzheimer’s disease: progress, problems, and perspectives
Popp et al. Cholesterol metabolism is associated with soluble amyloid precursor protein production in Alzheimer's disease
Dehelean et al. Trends in glycolipid biomarker discovery in neurodegenerative disorders by mass spectrometry
Vermeiren et al. The monoaminergic footprint of depression and psychosis in dementia with Lewy bodies compared to Alzheimer’s disease
Mehta et al. Advances in biomarker research in Parkinson’s disease
Pradeepkiran et al. Amyloid-β and phosphorylated tau are the key biomarkers and predictors of Alzheimer’s disease
Sawa et al. Impact of increased APP gene dose in Down syndrome and the Dp16 mouse model
Kovacs et al. Clinicopathological description of two cases with SQSTM1 gene mutation associated with frontotemporal dementia
Hirota et al. Distinct brain pathologies associated with Alzheimer’s disease biomarker-related phospho-tau 181 and phospho-tau 217 in App knock-in mouse models of amyloid-β amyloidosis
Gao et al. Clinical and neuropathological features associated with loss of RAB39B
Nagamine et al. Hypersialylation is a common feature of neurofibrillary tangles and granulovacuolar degenerations in Alzheimer's disease and tauopathy brains
Kawakami et al. Towards an understanding of the pathological basis of senile depression and incident dementia: Implications for treatment
Enzlein et al. Integrative single-plaque analysis reveals signature Aβ and lipid profiles in the Alzheimer’s brain
Kirkwood et al. Altered levels of visinin-like protein 1 correspond to regional neuronal loss in Alzheimer disease and frontotemporal lobar degeneration
Ben Khedher et al. Apolipoprotein E4–driven effects on inflammatory and neurotrophic factors in peripheral extracellular vesicles from cognitively impaired, no dementia participants who converted to Alzheimer's disease
Escamilla et al. Synaptic and extrasynaptic distribution of NMDA receptors in the cortex of Alzheimer's disease patients
Jia et al. Mitochondria-sequestered Aβ renders synaptic mitochondria vulnerable in the elderly with a risk of Alzheimer disease
van Kruining et al. Plasma ceramides relate to mild cognitive impairment in middle‐aged men: The Maastricht Study
Cleary et al. Neuron‐derived extracellular vesicles as a liquid biopsy for brain insulin dysregulation in Alzheimer's disease and related disorders